BMS and Exelixis target tumor suppression pathways.
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002227:Carbazoles; D016923:Cell Death / Q000187:drug effects; D002986:Clinical Trials as Topic; D018450:Disease Progression; D015195:Drug Design; D004345:Drug Industry / Q000191:economics; D016147:Genes, Tumor Suppressor / Q000502:physiology*; D006801:Humans; D007211:Indoles; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D002227:Carbazoles; D007211:Indoles; C053339:rebeccamycin